Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $42.6 million.

  • Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1100.97% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 1100.97%. This contributed to the annual value of $37.6 million for FY2024, which is 2797.94% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) is $42.6 million, which was up 1100.97% from $42.4 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $42.6 million during Q3 2025, and its lowest value of $20.3 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $26.8 million (2023), whereas its average is $29.8 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) soared by 67528.36% in 2021 and then surged by 184.01% in 2022.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $20.6 million in 2021, then rose by 19.78% to $24.6 million in 2022, then increased by 19.35% to $29.4 million in 2023, then grew by 27.98% to $37.6 million in 2024, then rose by 13.3% to $42.6 million in 2025.
  • Its last three reported values are $42.6 million in Q3 2025, $42.4 million for Q2 2025, and $39.3 million during Q1 2025.